| Name | VCE-004.8 | CAS# | 1818428-24-8 | |
|---|---|---|---|---|
| Price | ¥Inquiry/1g | Purity | 98.9% | |
| Stocking Period |
1 Day | Stock | In Stock |
| Detail
Product Information
EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. |